ZA200500693B - Oral pharmaceutical formualtion in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility - Google Patents
Oral pharmaceutical formualtion in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubilityInfo
- Publication number
- ZA200500693B ZA200500693B ZA200500693A ZA200500693A ZA200500693B ZA 200500693 B ZA200500693 B ZA 200500693B ZA 200500693 A ZA200500693 A ZA 200500693A ZA 200500693 A ZA200500693 A ZA 200500693A ZA 200500693 B ZA200500693 B ZA 200500693B
- Authority
- ZA
- South Africa
- Prior art keywords
- microcapsules
- active principle
- core
- release
- low solubility
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0209532A FR2842736B1 (fr) | 2002-07-26 | 2002-07-26 | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200500693B true ZA200500693B (en) | 2006-07-26 |
Family
ID=30011529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200500693A ZA200500693B (en) | 2002-07-26 | 2005-01-24 | Oral pharmaceutical formualtion in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility |
Country Status (17)
Country | Link |
---|---|
US (1) | US8652523B2 (xx) |
EP (1) | EP1524968B1 (xx) |
JP (2) | JP5430815B2 (xx) |
KR (1) | KR20050026515A (xx) |
CN (1) | CN1678295B (xx) |
AT (1) | ATE381927T1 (xx) |
AU (1) | AU2003269067B2 (xx) |
BR (1) | BR0312995A (xx) |
CA (1) | CA2493453C (xx) |
DE (1) | DE60318316T2 (xx) |
ES (1) | ES2298551T3 (xx) |
FR (1) | FR2842736B1 (xx) |
IL (1) | IL166383A0 (xx) |
MX (1) | MXPA05001077A (xx) |
PT (1) | PT1524968E (xx) |
WO (1) | WO2004010983A2 (xx) |
ZA (1) | ZA200500693B (xx) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
DE60325709D1 (de) | 2002-04-09 | 2009-02-26 | Flamel Tech Sa | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
BR0309093A (pt) | 2002-04-09 | 2005-02-09 | Flamel Tech Sa | Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina |
EP1742663A2 (en) | 2004-04-15 | 2007-01-17 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
FR2882259A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan |
FR2884145A1 (fr) * | 2005-04-06 | 2006-10-13 | Flamel Technologies Sa | Forme pharmaceutique orale de losartan |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
WO2006087394A1 (fr) * | 2005-02-21 | 2006-08-24 | Flamel Technologies | Forme pharmaceutique orale de losartan |
FR2885526B1 (fr) * | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
CN102846585A (zh) | 2006-03-28 | 2013-01-02 | 杰佛林制药公司 | 低剂量的双氯芬酸和β-环糊精的制剂 |
US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
KR101814186B1 (ko) | 2008-09-17 | 2018-03-14 | 키아스마 인코포레이티드 | 약제학적 조성물 및 연관된 투여방법 |
FR2936709B1 (fr) | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
FR2945947B1 (fr) | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Compositions pharmaceutiques flottantes a liberation controlee |
FR2945945B1 (fr) * | 2009-05-29 | 2011-07-29 | Flamel Tech Sa | Procede de preparation de particules creuses et leurs applications |
GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
NO2659881T3 (xx) * | 2012-04-30 | 2018-04-28 | ||
EP3253401B1 (en) | 2015-02-03 | 2025-04-02 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
AU2016388308B2 (en) | 2016-01-20 | 2022-08-04 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2019126125A1 (en) | 2017-12-20 | 2019-06-27 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
WO2020130649A1 (ko) * | 2018-12-19 | 2020-06-25 | 대화제약 주식회사 | Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물 |
US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2313915A1 (fr) | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
GB8414221D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Unit dosage form |
LU85943A1 (fr) | 1985-06-12 | 1987-01-13 | Galephar | Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation |
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
IT1227899B (it) | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
FI922107A0 (fi) * | 1991-05-10 | 1992-05-08 | Faulding F H & Co Ltd | Mikrokapselkomposition och foerfarande. |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
SE9402422D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
JPH0873345A (ja) | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
FR2732218B1 (fr) * | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
JPH09188617A (ja) | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | 徐放性医薬組成物 |
CN1228693A (zh) | 1996-06-28 | 1999-09-15 | 先灵公司 | 含有三唑类抗真菌化合物的口服组合物 |
WO1998026803A1 (fr) | 1996-12-19 | 1998-06-25 | Daiichi Pharmaceutical Co., Ltd. | Composition pharmaceutique pour administration par voie orale |
ATE318132T1 (de) | 1998-03-30 | 2006-03-15 | Jagotec Ag | Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung |
TW407058B (en) | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
ES2157731B1 (es) | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
EP1117384A1 (en) | 1998-10-01 | 2001-07-25 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6544556B1 (en) * | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
FR2816840B1 (fr) * | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
CA2444569C (en) * | 2001-04-18 | 2011-01-04 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
BR0309093A (pt) | 2002-04-09 | 2005-02-09 | Flamel Tech Sa | Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina |
DE60325709D1 (de) | 2002-04-09 | 2009-02-26 | Flamel Tech Sa | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
-
2002
- 2002-07-26 FR FR0209532A patent/FR2842736B1/fr not_active Expired - Fee Related
-
2003
- 2003-07-28 EP EP03750852A patent/EP1524968B1/fr not_active Expired - Lifetime
- 2003-07-28 KR KR1020057001365A patent/KR20050026515A/ko not_active Ceased
- 2003-07-28 CA CA2493453A patent/CA2493453C/fr not_active Expired - Lifetime
- 2003-07-28 JP JP2004523894A patent/JP5430815B2/ja not_active Expired - Lifetime
- 2003-07-28 AU AU2003269067A patent/AU2003269067B2/en not_active Expired
- 2003-07-28 DE DE60318316T patent/DE60318316T2/de not_active Expired - Lifetime
- 2003-07-28 WO PCT/FR2003/002382 patent/WO2004010983A2/fr active IP Right Grant
- 2003-07-28 MX MXPA05001077A patent/MXPA05001077A/es active IP Right Grant
- 2003-07-28 CN CN038199092A patent/CN1678295B/zh not_active Expired - Lifetime
- 2003-07-28 PT PT03750852T patent/PT1524968E/pt unknown
- 2003-07-28 US US10/522,252 patent/US8652523B2/en active Active
- 2003-07-28 AT AT03750852T patent/ATE381927T1/de active
- 2003-07-28 ES ES03750852T patent/ES2298551T3/es not_active Expired - Lifetime
- 2003-07-28 BR BR0312995-0A patent/BR0312995A/pt not_active IP Right Cessation
-
2005
- 2005-01-20 IL IL16638305A patent/IL166383A0/xx not_active IP Right Cessation
- 2005-01-24 ZA ZA200500693A patent/ZA200500693B/xx unknown
-
2013
- 2013-09-12 JP JP2013189905A patent/JP2014005289A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20050026515A (ko) | 2005-03-15 |
FR2842736B1 (fr) | 2005-07-22 |
JP5430815B2 (ja) | 2014-03-05 |
JP2006500332A (ja) | 2006-01-05 |
US20060165809A1 (en) | 2006-07-27 |
IL166383A0 (en) | 2006-01-16 |
JP2014005289A (ja) | 2014-01-16 |
AU2003269067A1 (en) | 2004-02-16 |
CN1678295A (zh) | 2005-10-05 |
CN1678295B (zh) | 2010-04-28 |
PT1524968E (pt) | 2008-03-13 |
DE60318316D1 (de) | 2008-02-07 |
DE60318316T2 (de) | 2008-12-11 |
MXPA05001077A (es) | 2005-06-06 |
FR2842736A1 (fr) | 2004-01-30 |
EP1524968A2 (fr) | 2005-04-27 |
AU2003269067B2 (en) | 2009-01-08 |
WO2004010983A2 (fr) | 2004-02-05 |
CA2493453C (fr) | 2012-05-22 |
CA2493453A1 (fr) | 2004-02-05 |
EP1524968B1 (fr) | 2007-12-26 |
US8652523B2 (en) | 2014-02-18 |
ES2298551T3 (es) | 2008-05-16 |
ATE381927T1 (de) | 2008-01-15 |
BR0312995A (pt) | 2005-06-28 |
WO2004010983A3 (fr) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200500693B (en) | Oral pharmaceutical formualtion in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility | |
WO2004010984A3 (fr) | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os | |
US9572773B2 (en) | Layered drug delivery device | |
Lu et al. | A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent | |
Fulzele et al. | Polymerized rosin: novel film forming polymer for drug delivery | |
Felton et al. | Influence of plasticizers on the adhesive properties of an acrylic resin copolymer to hydrophilic and hydrophobic tablet compacts | |
Maheshwari et al. | Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin | |
EP1051174B2 (fr) | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques | |
DK1663216T3 (da) | Tacrolimus-holdige sammensætninger med modificeret frigivelse | |
WO2007036671A3 (fr) | Microparticules enrobees a liberation modifiee d ' au moins un principe actif et forme galenique orale en comprenant | |
HUP0301887A2 (hu) | Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz | |
WO2008149440A1 (ja) | 速溶性及び可撓性を有するフィルム製剤 | |
CA2769046A1 (en) | Coating agent for the dip coating of capsule halves | |
CA2554052A1 (en) | Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile | |
WO2010076519A1 (fr) | Composition comprenant un actif de faible solubilite aqueuse | |
Zaid et al. | Development and stability evaluation of enteric coated Diclofenac sodium tablets using Sureteric. | |
JP6780412B2 (ja) | コーティング組成物ならびにコーティング製剤及びその製造方法 | |
Garg et al. | Effect of formulation parameters on the release characteristics of propranolol from asymmetric membrane coated tablets | |
DE60200202D1 (de) | Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung | |
WO2017149897A1 (ja) | 癒着防止材 | |
US20170266931A1 (en) | Omniphobic materials for bio-applications | |
AU4765300A (en) | Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations | |
MX2007005124A (es) | Composiciones farmaceuticas espontaneamente dispersables. | |
Patel et al. | A review on time dependent systems for colonic delivery | |
Thakor et al. | Development and evaluation of osmotic drug delivery system for calcium channel blocker drug |